Page last updated: 2024-09-04

ptk 787 and 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide

ptk 787 has been researched along with 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide in 2 studies

Compound Research Comparison

Studies (ptk 787)	Trials (ptk 787)	Recent Studies (post-2010) (ptk 787)	Studies (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)	Trials (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)	Recent Studies (post-2010) (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)
5	0	1	17	0	3

Protein Interaction Comparison

Protein	Taxonomy	2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide (IC50)
Tyrosine-protein kinase ABL1	Homo sapiens (human)	2.82
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	0.38
Platelet-derived growth factor receptor beta	Homo sapiens (human)	0.64
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	0.236
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	0.1365
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	0.018
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	0.0506

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J	1
Aono, H; Ban, M; Honda, T; Inaba, T; Kaneko, Y; Okamoto, K; Tajima, H; Takeno, Y	1

Other Studies

2 other study(ies) available for ptk 787 and 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide

Article	Year
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26 Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor	2002
Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9 Topics: Algorithms; Angiogenesis Inhibitors; Catalytic Domain; Crystallography, X-Ray; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Inhibitory Concentration 50; Molecular Conformation; Phthalazines; Pyridines; Structure-Activity Relationship; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2008

Article

Year

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

Journal of medicinal chemistry, 2002, Dec-19, Volume: 45, Issue:26

Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor

2002

Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity.

Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9

Topics: Algorithms; Angiogenesis Inhibitors; Catalytic Domain; Crystallography, X-Ray; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Inhibitory Concentration 50; Molecular Conformation; Phthalazines; Pyridines; Structure-Activity Relationship; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2008